The World Health Organization's Evidence Considerations for Vaccine Policy Development (ECVP) focuses on TB vaccines intended for adults and adolescents and is designed to support the product development, regulatory approval, introduction, access and widespread use in LMICs of new TB…
Informed by the acknowledged high need for new TB vaccines to support the fight to end TB, the World Health Organization's Preferred Product Characteristics outlines priority characteristics for TB vaccines in the short-term.
The World Health Organization's Catalyzing solutions for equitable global access and sustainable financing for novel tuberculosis vaccines for adults and adolescents report assesses country readiness, demand and supply projections, product development pathways and the global financing landscape to understand potential uncertainties…
From Forest to Factory: Tracing the Supply Chains for Two Modern Adjuvants of Global Health Importance — QS-21 and MPL provides a first-of-its-kind analysis of the global supply chains of two key adjuvants used in several of the world’s most…